vaxzevria

Vaccineexperimental

Clinical trial activity

4 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started May 10, 2021 (NCT04907331)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05387317Phase 3Feb 28, 2023Coalition for Epidemic Preparedness Innovations, Government of Indonesia, Murdoch University, Padjadjaran University, The Peter Doherty Institute, University of Indonesia
NCT05534035Phase 3Feb 3, 2023Everest Medicines
NCT05188677Phase 3Jun 13, 2022Clover Biopharmaceuticals
NCT04907331Phase 2May 10, 2021Medical University Innsbruck, Medical University of Graz, Medical University of Vienna
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Clover BiopharmaceuticalsFor profit1112022
Coalition for Epidemic Preparedness InnovationsAcademic/Hospital1012023
Everest MedicinesFor profit1112023
Government of IndonesiaGovernment1012023
Medical University InnsbruckAcademic/Hospital1112021
Medical University of GrazAcademic/Hospital1012021
Medical University of ViennaAcademic/Hospital1012021
Murdoch UniversityAcademic/Hospital1112023
Padjadjaran UniversityAcademic/Hospital1012023
The Peter Doherty InstituteAcademic/Hospital1012023
University of IndonesiaAcademic/Hospital1012023
11 organizations
Page 1 / 1